Trial Profile
A Multi-Center, Open-Label, Single-dose, Single-Arm Study to Evaluate the Usability of Subcutaneously Administered Sumatriptan Delivered Via the Intraject® System in Adult Patients During Acute Migraine Attack
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Nov 2022
Price :
$35
*
At a glance
- Drugs Sumatriptan (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Zogenix
- 04 Oct 2007 New trial record.